FDA Expert Panel To Review Serevent, Foradil Safety; Asthma-Related Deaths A Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee meets on the benefits and risks of the beta-2 agonist class for the third time in three years.